Literature DB >> 10511459

Class A beta-lactamases--enzyme-inhibitor interactions and resistance.

Y Yang1, B A Rasmussen, D M Shlaes.   

Abstract

Beta-Lactamases of Ambler's Class A are the most commonly encountered mechanism of bacterial resistance to beta-lactam antibiotics. In the face of selective pressure arising from use of either newer cephalosporins or beta-lactam/beta-lactamase inhibitor combinations, mutations arose among Class A beta-lactamase genes, leading to resistance. Clavulanic acid, a naturally occurring clavam, and the penicillanic acid sulfones sulbactam and tazobactam are the inhibitors in clinical use. This review focuses on the mechanism of inhibition by these currently marketed beta-lactamase inhibitors and on the mechanism by which specific amino acid substitutions might lead to resistance. The key amino acid positions important for inhibitor-resistance include Met69, Ser130, Arg244, Arg275, and Asn276. Ser130 is vital to the chemical mechanism of inhibition. Arg244 appears to be coordinated to Arg275 and Asp276 by hydrogen bonds. Arg244 is involved in positioning beta-lactams, especially penicillins and beta-lactamase inhibitors, via their carboxyl groups. Site-directed mutagenesis studies confirm the role of Arg244 and its coordinating partners in beta-lactam turnover and in the reactions leading to enzyme inactivation. This mechanism is dependent on the donation of a proton via a water coordinated to Arg244 and Val216 to clavulanic acid to allow formation of a favorable leaving group. This proton donation is probably not required for formation of a favorable leaving group for the sulfone inhibitors sulbactam and tazobactam. Therefore, some amino acid substitutions have differing effects on inhibition by clavulanic acid compared with the penicillanic acid sulfones. Met69 may play a more structural role in beta-lactam positioning within the oxyanion hole.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511459     DOI: 10.1016/s0163-7258(99)00027-3

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  14 in total

1.  What's New in beta-lactamases?

Authors:  Patricia A. Bradford
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.

Authors:  Kajal B Larson; Yogesh T Patel; Susan Willavize; John S Bradley; Elizabeth G Rhee; Luzelena Caro; Matthew L Rizk
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Dynamical aspects of TEM-1 beta-lactamase probed by molecular dynamics.

Authors:  Danilo Roccatano; Gianluca Sbardella; Massimiliano Aschi; Gianfranco Amicosante; Cecilia Bossa; Alfredo Di Nola; Fernando Mazza
Journal:  J Comput Aided Mol Des       Date:  2005-05       Impact factor: 3.686

4.  Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Authors:  Feng Wang; Craig Cassidy; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 5.  Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Authors:  George G Zhanel; Phillip Chung; Heather Adam; Sheryl Zelenitsky; Andrew Denisuik; Frank Schweizer; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Andrew Walkty; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

Review 6.  Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents.

Authors:  M Shaheer Malik; Saleh A Ahmed; Ismail I Althagafi; Mohammed Azam Ansari; Ahmed Kamal
Journal:  RSC Med Chem       Date:  2020-01-29

7.  An analysis of why highly similar enzymes evolve differently.

Authors:  Fahd K Majiduddin; Timothy Palzkill
Journal:  Genetics       Date:  2003-02       Impact factor: 4.562

8.  The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Authors:  Sarah M Drawz; Christopher R Bethel; Kristine M Hujer; Kelly N Hurless; Anne M Distler; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

9.  Preparation of novel selenopenams by intramolecular homolytic substitution.

Authors:  Michael W Carland; Carl H Schiesser
Journal:  Molecules       Date:  2004-05-31       Impact factor: 4.411

10.  Inhibitor-sensitive AmpC beta-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins.

Authors:  Yohei Doi; Jun-ichi Wachino; Masaji Ishiguro; Hiroshi Kurokawa; Kunikazu Yamane; Naohiro Shibata; Keigo Shibayama; Keiko Yokoyama; Haru Kato; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.